Why the study?
Certain chemotherapeutic agents increase cardiotoxicity risk, and this study aimed to evaluate whether protocatechuic acid protects cardiomyocytes against toxicity induced by doxorubicin and arsenic trioxide.
Does protocatechuic acid prevent doxorubicin- and arsenic trioxide-induced toxicity in H9C2 cardiomyocytes?
Population
H9C2 cardiomyocytes
Comparison
PCA pretreatment (1-100 μM) before DOX (1 μM) or ATO (35 μM) exposure vs untreated controls
Design
In vitro experimental study
Authors
Loading...
May support preclinical testing of PCA for anthracycline/arsenic cardiotoxicity; leaves open translation to in vivo or clinical use.
Does protocatechuic acid prevent doxorubicin- and arsenic trioxide-induced toxicity in H9C2 cardiomyocytes?
Protocatechuic acid demonstrates cardioprotective effects against doxorubicin- and arsenic trioxide-induced toxicity in vitro by reducing oxidative stress and TLR4 expression.
Fatemeh et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: